André Engling

Title: The Innovative Mind of Andre Engling

Introduction

Andre Engling, a talented inventor based in Bad Homburg, Germany, has made significant strides in the field of immunotherapy. With a focus on utilizing immunoconjugates to target specific cells, Engling holds two notable patents that address diseases associated with CD138 expressing cells. Her work demonstrates a commitment to advancing medical science and improving treatment options for patients.

Latest Patents

Engling's latest patents include groundbreaking methods and compositions for treating diseases associated with target cells that express CD138. One patent discloses a method involving an immunoconjugate that combines an engineered targeting antibody with an effector molecule, administered in a multiple dose regimen. This regimen includes at least two doses, with the aggregate dose serving as the aggregate maximum tolerable dose (AMTD) or a fraction thereof. The innovation surpasses the doses that could lead to dose-limiting toxicity (DLT) or maximum tolerable dose (MTD) when used as a single dose. Another patent emphasizes the use of immunoconjugates targeting CD138 as the sole active ingredient, part of a treatment regime, or in combination with other anticancer therapies, showcasing the versatile applications of her inventions in combatting diseases.

Career Highlights

Throughout her career, Andre Engling has contributed significantly to her field, having worked with reputable companies such as Biotest AG and Immunogen, Inc. Her experience at these organizations has allowed her to refine her innovative approach to therapy development and apply her findings in practical settings.

Collaborations

Engling has collaborated with notable professionals in her field, including Gregor Schulz and Frank Osterroth. These collaborations have furthered her research and development endeavors, ultimately enhancing the impact of her inventions on the medical community.

Conclusion

In summary, Andre Engling is a remarkable inventor whose work on immunoconjugates targeting CD138 has the potential to transform disease treatment. With two impactful patents to her name and a strong career supported by significant collaborations, Engling exemplifies innovation in the medical research field. Her contributions continue to pave the way for new therapeutic options in immunotherapy, benefiting patients globally.